Sherine Solomon, NP
Family · Farmington, CTNPI 1336523406
Payments from drug & device makers
Across 97 payments — averaging $39.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$699
- Novo Nordisk$656
- Amgen$428
- Xeris Pharmaceuticals, Inc.$380
- Medtronic$379
- Cequr Corporation$229
- plus $1K from 14 others
What the payments were for
- Travel & lodging$10%
- Food & beverage$3,803100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $699 |
| Novo Nordisk | 39 | $656 |
| Amgen | 8 | $428 |
| Xeris Pharmaceuticals, Inc. | 10 | $380 |
| Medtronic | 6 | $379 |
| Cequr Corporation | 3 | $229 |
| Tandem Diabetes Care, Inc. | 2 | $197 |
| Sequel Med Tech, LLC | 4 | $194 |
| Radius Health, Inc. | 1 | $122 |
| Dexcom, Inc. | 1 | $115 |
| Corcept Therapeutics | 1 | $115 |
| Lilly USA, LLC | 5 | $103 |
| AbbVie | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Bayer | 1 | $27 |
| GSK | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $13 |
| BETA Bionics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$630
- GVOKE HYPOPEN$250
- TEPEZZA$232
- MINIMED 780G$227
- t:slim X2 Insulin Pump with Control-IQ$152
- TWIIST$123
- Ozempic$123
- Tymlos$122
- DEXCOM G6 TRANSMITTER$115
- Korlym$115
- CeQur Simplicity$109
How this compares
$3,804 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 366 | $485,417 |
| MounjaroTirzepatide | 187 | $205,515 |
| JardianceEmpagliflozin | 135 | $192,436 |
| TrulicityDulaglutide | 73 | $93,141 |
| Tresiba Flextouch U-200Insulin Degludec | 90 | $89,068 |
| RybelsusSemaglutide | 49 | $88,545 |
| Tresiba Flextouch U-100Insulin Degludec | 108 | $64,879 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $60,703 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $50,919 |
| Humalog Kwikpen U-200Insulin Lispro | 25 | $47,085 |
| FarxigaDapagliflozin Propanediol | 28 | $44,842 |
| JanuviaSitagliptin Phosphate | 34 | $44,091 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $43,163 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $30,381 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $28,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $656 | $584,055438 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $103 | $312,678302 claims |
| AbbVieSynthroid | $33 | $4,55941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.
Other family in Farmington
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.